Latest & greatest articles for prednisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisone

41. Rayos (prednisone) delayed release tablet

Rayos (prednisone) delayed release tablet Drug Approval Package: Rayos (prednisone) NDA #202020 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Rayos (prednisone) delayed release tablet 1 mg, 2 mg, 5 mg Company: Horizon Pharma, Inc. Application No.: 202020 Approval Date: 07/26/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2012

42. Deflazacort Versus Prednisone: A Systematic Comparison of two Steroids in the Treatment of Duchenne Muscular Dystrophy

Deflazacort Versus Prednisone: A Systematic Comparison of two Steroids in the Treatment of Duchenne Muscular Dystrophy "Deflazacort Versus Prednisone: A Systematic Comparison of two Steroids" by Jaime L. Ulrich < > > > > > Title Author Date of Award Summer 8-11-2012 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Robert P. Rosenow, Pharm.D., O.D. Second Advisor Annjanette Sommers PA-C, MS Rights . Abstract Background: Duchenne muscular (...) dystrophy (DMD) is a genetic disorder in males resulting in muscle weakness leading to loss of ambulation and progression to death by pulmonary and cardiac dysfunction. It has been documented both steroids deflazacort and prednisone delay muscle degeneration but not many studies outline the differences between the two including side effect profiles. Deflazacort is not yet available in the US. This systematic review compiles recent data to compare deflazacort to prednisone in the treatment of DMD boys

Pacific University EBM Capstone Project2012

43. Cabazitaxel (Jevtana) - In combination with prednisone or prednisolone, cabazitaxel is licensed for the treatment of patients with hormone refractory metastatic prostate cancer

Cabazitaxel (Jevtana) - In combination with prednisone or prednisolone, cabazitaxel is licensed for the treatment of patients with hormone refractory metastatic prostate cancer

Scottish Medicines Consortium2011

44. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy 21753160 2011 08 03 2011 09 30 2016 12 15 1526-632X 77 5 2011 Aug 02 Neurology Neurology Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. 444-52 10.1212/WNL.0b013e318227b164 To perform a double-blind, randomized study comparing efficacy and safety of daily and weekend prednisone in boys with Duchenne muscular dystrophy (DMD). A total of 64 boys with DMD who were (...) between 4 and 10 years of age were randomized at 1 of 12 centers of the Cooperative International Neuromuscular Research Group. Efficacy and safety of 2 prednisone schedules (daily 0.75 mg/kg/day and weekend 10 mg/kg/wk) were evaluated over 12 months. Equivalence was met for weekend and daily dosing of prednisone for the primary outcomes of quantitative muscle testing (QMT) arm score and QMT leg score. Secondary strength scores for QMT elbow flexors also showed equivalence between the 2 treatment

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

45. Bendamustine (Levact) - for the front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone

Bendamustine (Levact) - for the front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone Published 11 April 2011 Statement of Advice bendamustine 2.5mg/mL powder for concentrate for solution for infusion (Levact ®) (No: 700/11) Napp Pharmaceuticals Limited 04 March 2011 ADVICE: in the absence of a submission from the holder of the marketing authorisation bendamustine (Levact ®) is not recommended for use within NHS Scotland (...) . Indication under review: for the front line treatment of multiple myeloma (Durie-Salmon stage II with progress or stage III) in combination with prednisone for patients older than 65 years who are not eligible for autologous stem cell transplantation and who have clinical neuropathy at time of diagnosis precluding the use of thalidomide or bortezomib containing treatment. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we

Scottish Medicines Consortium2011

46. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial 20940200 2010 11 30 2011 01 03 2015 11 19 1527-7755 28 34 2010 Dec 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared (...) with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. 5101-9 10.1200/JCO.2010.29.8216 The combination of bortezomib-melphalan-prednisone (VMP) is a new standard of care for newly diagnosed multiple myeloma. This phase III study examined the efficacy of the four-drug combination of bortezomib-melphalan-prednisone-thalidomide (VMPT) followed by maintenance with bortezomib-thalidomide (VMPT-VT) compared with VMP treatment alone in untreated multiple

EvidenceUpdates2011

47. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis

Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis Teuffel O, Kuster SP, Hunger SP, Conter V, Hitzler J, Ethier MC, Shah PS, Beyene J, Sung L CRD (...) summary This review compared dexamethasone with prednisone during induction chemotherapy in children with acute lymphoblastic leukaemia and found that dexamethasone was more efficacious than prednisone but was also associated with more toxicity. Therefore, it was unclear whether this short-term superiority would translate to superior overall survival with longer follow-up. These conclusions are likely to be reliable. Authors' objectives To compare the efficacy and toxicity of dexamethasone

DARE.2011

48. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial.

Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. 21733570 2011 07 25 2011 09 06 2015 06 16 1474-547X 378 9788 2011 Jul 23 Lancet (London, England) Lancet Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial. 338-46 10.1016/S0140-6736(11)60934-3 Glucocorticoids are the mainstay of treatment of idiopathic retroperitoneal fibrosis, but they often have (...) substantial toxic effects. Several reports have suggested tamoxifen as an alternative to glucocorticoids. We compared the efficacy of prednisone with that of tamoxifen in maintainance of remission in patients with idiopathic retroperitoneal fibrosis. In this open-label, randomised controlled trial, we enrolled patients aged 18-85 years with newly diagnosed idiopathic retroperitoneal fibrosis at the Parma Hospital, Parma, Italy, between Oct 1, 2000, and June 30, 2006. After induction therapy with 1 mg/kg

Lancet2011

49. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial

Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial 19805692 2009 11 09 2010 01 06 2014 11 20 1527-7755 27 32 2009 Nov 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate (...) /m(2) on days 1 to 5 of a 35-day cycle and prednisone 5 mg twice daily or placebo (n = 315) and prednisone 5 mg twice daily. Primary end points were progression-free survival and overall survival (OS). The secondary end point was time to pain progression (TPP). A 33% reduction (hazard ratio [HR] = 0.67; 95% CI, 0.57 to 0.77; P < .001) was observed in the risk of progression or death with satraplatin versus placebo. This effect was maintained irrespective of prior docetaxel treatment

EvidenceUpdates2010

50. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. 20888992 2010 10 04 2010 10 19 2015 11 19 1474-547X 376 9747 2010 Oct 02 Lancet (London, England) Lancet Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. 1147-54 10.1016/S0140-6736(10)61389-X Cabazitaxel is a novel (...) tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment. We undertook an open-label randomised phase 3 trial in men with metastatic castration-resistant prostate cancer who had received previous hormone therapy, but whose disease had

Lancet2010

51. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial

Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial 19451428 2009 07 31 2009 08 20 2013 11 21 1527-7755 27 22 2009 Aug 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. 3664-70 10.1200/JCO.2008.21.0948 (...) Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma. The addition of thalidomide to this combination demonstrated a survival benefit for patients age 65 to 75 years. This randomized, placebo-controlled, phase III trial investigated the efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed myeloma. Between April 2002 and December 2006, 232 previously untreated patients with myeloma, age 75

EvidenceUpdates2009

52. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study 19255334 2009 03 31 2009 04 29 2016 10 19 1527-7755 27 10 2009 Apr 01 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent (...) lymphoma: results of the randomized phase III ECOG1496 Study. 1607-14 10.1200/JCO.2008.17.1561 To determine if maintenance rituximab (MR) after standard chemotherapy improves progression-free survival (PFS) in advanced-stage indolent lymphoma. Patients with stage III-IV indolent lymphoma with responding or stable disease after cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy were stratified by initial tumor burden, residual disease after CVP (minimal or gross), and histology

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

53. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy

Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy 19297556 2009 03 30 2009 05 22 2016 10 19 1533-3450 20 4 2009 Apr Journal of the American Society of Nephrology : JASN J. Am. Soc. Nephrol. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. 901-11 10.1681/ASN.2008060665 Patients with lupus membranous nephropathy (LMN) are at substantial long-term risk for morbidity (...) and mortality associated with protracted nephrotic syndrome, including ESRD. The optimal treatment for this condition is controversial. Forty-two patients with LMN participated in a randomized, controlled trial to compare adjunctive immunosuppressive drugs with prednisone alone. Adjunctive regimens included either cyclosporine (CsA) for 11 mo or alternate-month intravenous pulse cyclophosphamide (IVCY) for six doses; the control group received alternate-day prednisone alone. Median proteinuria was 5.4 g/d

EvidenceUpdates2009 Full Text: Link to full Text with Trip Pro

54. Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy

Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone (...) as first line treatment of patients with untreated multiple myeloma, aged GE 65 years or ineligible for high dose chemotherapy All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Thalidomide (Thalidomide Pharmion®) in combination with melphalan and prednisone as first line treatment

Health Technology Assessment (HTA) Database.2009

56. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. 19264687 2009 03 06 2009 03 11 2014 11 20 1533-4406 360 10 2009 Mar 05 The New England journal of medicine N. Engl. J. Med. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. 985-93 10.1056/NEJMoa0805435 Eosinophilic inflammation, which may be a consequence of interleukin-5 action, is a characteristic feature of some forms of asthma. However, in three previous clinical trials involving patients with asthma (...) , blockade of this cytokine did not result in a significant improvement in outcomes. We studied the prednisone-sparing effect of mepolizumab, a monoclonal antibody against interleukin-5, in a rare subgroup of patients who have sputum eosinophilia and airway symptoms despite continued treatment with prednisone. Secondary objectives were to examine its effect on the number of eosinophils in sputum and blood, symptoms, and airflow limitation. In this randomized, double-blind, parallel-group trial involving

NEJM2009

57. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer

Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer 18794543 2008 11 07 2008 12 04 2013 11 21 1527-7755 26 32 2008 Nov 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer (...) . 5261-8 10.1200/JCO.2008.16.9524 To assess the efficacy and toxicity of the addition of estramustine to docetaxel (D) for the treatment of metastatic hormone-refractory prostate cancer. One hundred fifty patients were randomly assigned to D alone (35 mg/m(2) on days 2 and 9, every 3 weeks) or D in combination with estramustine (D/E; 280 mg orally three times a day on days 1 to 5 and 8 to 12, every 3 weeks). All patients received prednisone (10 mg/d). The primary end point

EvidenceUpdates2008

58. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.

Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. 18207016 2008 01 21 2008 01 31 2015 06 16 1474-547X 371 9608 2008 Jan 19 Lancet (London, England) Lancet Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. 205-14 10.1016 (...) /S0140-6736(08)60132-4 Circadian rhythms are changed in patients with rheumatoid arthritis. A new modified-release delivery system has been developed which adapts the release of the administered glucocorticoid to the circadian rhythms of endogenous cortisol and disease symptoms to improve the benefit-risk ratio of glucocorticoid therapy in rheumatoid arthritis. We aimed to assess the efficacy and safety of a new modified-release prednisone tablet compared with immediate-release prednisone in patients

Lancet2008

59. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. 18753647 2008 08 28 2008 09 03 2015 11 19 1533-4406 359 9 2008 Aug 28 The New England journal of medicine N. Engl. J. Med. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. 906-17 10.1056/NEJMoa0801479 The standard treatment for patients with multiple myeloma who are not candidates for high-dose therapy is melphalan and prednisone. This phase 3 study compared the use (...) of melphalan and prednisone with or without bortezomib in previously untreated patients with multiple myeloma who were ineligible for high-dose therapy. We randomly assigned 682 patients to receive nine 6-week cycles of melphalan (at a dose of 9 mg per square meter of body-surface area) and prednisone (at a dose of 60 mg per square meter) on days 1 to 4, either alone or with bortezomib (at a dose of 1.3 mg per square meter) on days 1, 4, 8, 11, 22, 25, 29, and 32 during cycles 1 to 4 and on days 1, 8, 22

NEJM2008

60. A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer

A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer Journals Library An error has occurred in processing the XML

NIHR HTA programme2007